MaxCyte’s Q4 Earnings Call Contradictions: Stabilization, SPL Pipeline Optimism Clash With Back-half Revenue Guidance, Program Rationalization Impact

Date of Call: Mar 24, 2026

Financials Results

• Revenue: $33M for full year, down 15% YOY from $38.6M in 2024. Q4 revenue $7.3M, down 16% YOY.
• Gross Margin: 78% in Q4 2025, up from 74% in Q4 2024. Non-GAAP adjusted gross margin was 78% vs 84% prior year.

Guidance:

• Total revenue for 2026 expected in the range of $30M-$32M, consisting of $25M-$27M core revenue and $5M SPL program-layer revenue.
• Core revenue expected to be back-half weighted, with Q1 as the lightest quarter.
• SPL program-related revenue guided to $5M in 2026, including ~$2M of expected royalty revenue from commercial stage customer ramping through the year.
• Expect ~$4M in core revenue headwind from SPL customers (half from PAs, half from leases) due to inventory management and manufacturing reorganization.
• SeQure Dx expected year-over-year growth in 2026.
• Cash equivalents and investments anticipated to be at least $136M at end of 2026.

Business Commentary:

Financial Performance and Revenue Decline:

• MaxCyte reported $33 million in total revenue for the full year, a 15% decline from $38.6 million in 2024.
• The decrease was driven by a decline in both core revenue and SPL program-related revenue, impacted by program consolidation, rationalization, and reduced purchasing activity from a major customer.

Strategic Product Launch and Market Positioning:

• MaxCyte launched the ExPERT DTx, a new 96-well electroporation platform, in February 2026, aiming to enhance early research and development capabilities.
• The launch is expected to contribute to both instrument and processing assembly revenue in 2026 and beyond, leveraging MaxCyte's electroporation expertise and offering a seamless path from discovery to clinical use.

Core Revenue and Customer Dynamics:

• Core revenue for the full year was $29.6 million, down 9% from 2024, with a significant $4 million headwind from SPL customers due to inventory management and manufacturing reorganization.
• The revenue decline is attributed to the largest customer's supply chain reorganization and inventory drawdown, alongside program rationalization impacting other SPL customers.

SeQure Dx Acquisition and Integration:

• SeQure Dx contributed $1.1 million in total revenue in 2025, with assay services and licenses.
• Despite lower-than-expected performance in 2025 due to integration challenges, MaxCyte anticipates year-over-year growth for SeQure Dx in 2026, driven by the increasing importance of off-target risk assessment in gene-edited therapies.

Guidance and Future Outlook:

• For 2026, MaxCyte expects total revenue to range from $30 million to $32 million, with a back-half weighted distribution.
• The guidance considers the stabilization of revenue from SPL customers and the ramp-up of commercial royalties, with a focus on pivotal clinical programs expected to drive future growth.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed confidence in the business model and future growth, stating 'I feel very good about 2026, just as good if not better about the future years.' They highlighted meaningful progress, a new product launch (ExPERT DTx), strong balance sheet, and optimism around pivotal programs and commercial ramp of Casgevy.

Q&A:

• Question from Dan Arias (Stifel): Given improving industry data, why is core revenue expected to decline more in 2026? Are you losing share?
  Response: Attributed the decline to specific short-term headwinds from SPL customers (inventory drawdowns, manufacturing reorganization, program exits), not a deterioration in business fundamentals or industry demand. Expressed confidence in growth from new products, pivotal programs, and later-stage SPLs.

• Question from Dan Arias (Stifel): Does the core revenue outlook assume industry demand improves, or is current demand sufficient?
  Response: Current guidance does not rely on an improvement in industry demand; it represents the base case. Any further demand would be upside.

• Question from Matt Hewitt (Craig-Hallum Capital Group): What is the revenue pipeline and timeline for the new ExPERT DTx product?
  Response: DTx revenue expected to trickle in second half of 2026, with significant traction anticipated in future years. It is already with beta users and seeing early sales.

• Question from Matt Hewitt (Craig-Hallum Capital Group): How are potential milestones from four pivotal programs factored into guidance?
  Response: Guidance assumes at least two milestones in 2026, with potential for four; already received one seven-figure milestone in Q1.

• Question from Jacob (William Blair): What is the visibility and cadence for SPL signings in 2026?
  Response: Confident in signing at least 3-5 SPLs in 2026, with timing dependent on customer development cycles; research to SPL conversion takes 12-18 months.

• Question from Jacob (William Blair): Can you quantify expectations for DTx revenue in the back half?
  Response: Will provide updates; expects more than a trickle in second half 2026 and more material contributions in 2027.

• Question from Chad Wiatrowski (TD Cowen): What is baked into 2026 guidance for SeQure Dx contribution and royalty visibility?
  Response: SeQure Dx expected material year-over-year growth in 2026. Royalty revenue of ~$2M expected from commercial stage customer ramping through the year.

• Question from Chad Wiatrowski (TD Cowen): How do you see long-term opportunity for ex vivo edits given in vivo headwinds?
  Response: Remains a strong believer in ex vivo cell therapy; increasing edit complexity favors ex vivo, and traction is starting to return.

• Question from Matt Ito (Stephens): What are you hearing from customers on macro environment and demand for FY 2026?
  Response: Current guidance is not contingent on improved demand; it reflects building from a new base after SPL customer losses. Comfortable with $6M core revenue in Q1, expecting uptick and second-half weighting.

• Question from Chad Wiatrowski (TD Cowen): Is DTx early orders mix existing or new customers?
  Response: Mix of both; targeting current customers for convenience and new customers, including for in vivo discovery.

Contradiction Point 1

Assessment of Business Environment and Customer Demand

Contradictory statements on market stabilization versus continued caution.

Matt Ito (Stephens) - Matt Ito (Stephens)

2025Q4: The core revenue guidance is back-half weighted and does not rely on an improvement in industry demand or customer capital spending. - [Maher Masoud](CFO)

How are customers' views on the macro environment, given improved funding, influencing expectations for demand in FY2026? - Matthew Larew (William Blair)

20251113-2025 Q3: We do see stabilization. ... But we're starting to see that some of the concerns... related to NIH funding... and... changes at the FDA... That seems to be stabilizing... - [Maher Masoud](CFO)

Contradiction Point 2

Outlook for New SPL Signings

Contradiction on the expected timing and certainty of signing new SPL agreements.

Jacob (William Blair, on for Matt Larew) - Jacob (William Blair, on for Matt Larew)

2025Q4: The company expects to sign at least 3 new SPLs in 2026, in line with the historical 3-5 per year average. The timing can vary... - [Maher Masoud](CFO) & [Sean Menarguez](COO)

Okay, let's tackle this query. The user wants me to rewrite the input into a single concise earnings-call question. The input is: "What is the visibility and expected cadence for new SPL signings in 2026?" First, I need to understand the key components here. The user is asking about "visibility" and "expected cadence" for new signings in the SPL (probably a sports league, maybe the Singapore Premier League or another league) in 2026. In the context of an earnings call, companies often discuss future plans, including player acquisitions. "Visibility" here likely refers to how clear or certain the company is about these signings. "Cadence" would relate to the timing or frequency of these signings.The challenge is to make this into a concise question. The original question is already a question, so I need to see if it can be rephrased to be more precise without losing meaning. The user's instruction says to output exactly one line, only the final question, ending with a question mark if a rewrite is possible. If the input isn't a question or is too vague, output it as-is.The original input is a valid question, but maybe it can be made more concise. "Visibility" and "expected cadence" are both important. Perhaps "timeline" could replace "cadence," but "cadence" is more about the rhythm or frequency. Maybe "schedule" or "timing" would work. Let me check synonyms for "cadence" in this context. Alternatively, combining the two parts: "What is the visibility and expected schedule for new SPL signings in 2026?" But "schedule" might not capture the frequency aspect. "Cadence" is a bit jargon-y but might be standard in certain industries. Alternatively, "What is the expected timeline and clarity on new SPL signings for 2026?" But "clarity" might not be as precise as "visibility." Wait, the original uses "visibility" which in business terms often refers to how much they can see or predict about future events. So "visibility" is about how certain or clear they are. So the question is asking both about the clarity of the signings and the expected timing. Is there a way to make this more concise? Maybe "What is the expected timeline for new SPL signings in 2026?" but that removes the "visibility" part. The user might be concerned about both the certainty and the schedule. But the user's instruction says to make it into one concise question. Maybe combining the two aspects: "What is the visibility and expected cadence of new SPL signings in 2026?" That's already concise. The original input is a question, so if it's acceptable as-is, maybe we don't need to change it. But the user wants a rewrite if possible. Wait, the original input is "What is the visibility and expected cadence for new SPL signings in 2026?" Maybe changing "for" to "of" would make it slightly more concise: "What is the visibility and expected cadence of new SPL signings in 2026?" But that's a minor change. Alternatively, "What is the expected cadence and visibility for new SPL signings in 2026?" The order doesn't matter. Since the original is already a clear question, maybe the best approach is to just ensure it's as concise as possible without altering the meaning. The user might prefer to keep the original phrasing if it's already clear. But the user's example in the instructions shows that if the input is a question and can be rewritten, we should. So perhaps the original is acceptable. However, the user might want to make sure it's in the most concise form. Alternatively, maybe "expected cadence" can be "timeline." So "What is the visibility and expected timeline for new SPL signings in 2026?" But "cadence" might be more specific to the frequency or rhythm. In the end, the original question is already concise. The user's instruction says if a rewrite is possible, output the final question. Since the original is a valid question, but perhaps can be made slightly more concise, I'll adjust it if possible. Changing "for" to "of" might be better. So the final question would be: "What is the visibility and expected cadence of new SPL signings in 2026?" with the question mark. But the user's input ends with a question mark. The output must end with a question mark if a rewrite is possible. Since the original ends with a question mark, and we are allowed to rewrite, the output should be the rewritten version. So the final answer would be the original, slightly adjusted for preposition if needed. However, "for" is correct here. Alternatively, maybe "What is the visibility and expected cadence for - Matthew Hewitt (Craig-Hallum Capital Group)

20251113-2025 Q3: I see 3 to 5 SPLs next year and for the foreseeable future as very doable... The funnel is there. It is strong and getting stronger... We're working with them now where they're 2 years away from signing an SPL... I still feel confident we can continue to sign 3 to 5 next year... - [Maher Masoud](CFO)

Contradiction Point 3

Quarterly Revenue Cadence

Contradiction on the expected timing of core revenue within the fiscal year.

Matt Ito (Stephens) - Matt Ito (Stephens)

2025Q4: The core revenue guidance is back-half weighted and does not rely on an improvement in industry demand or customer capital spending. - [Maher Masoud](CEO)

How is improved funding impacting customer sentiment on the macro environment and demand expectations for FY2026? - Rohan Walcott (Stifel - on behalf of Dan Arias)

2025Q2: The revised revenue guidance for H2 is expected to be slightly weighted towards Q4, but not materially so. - [Maher Masoud](CEO)

Contradiction Point 4

SPL Pipeline and Program Rationalization

Contradiction on whether program rationalization is an isolated event or part of a broader trend affecting the pipeline.

Dan Arias (Stifel) - Dan Arias (Stifel)

2025Q4: Declined revenue is due to... 2) Program rationalization (6 SPL clinical programs discontinued). - [Maher Masoud](CEO)

Given improving industry data, why is core revenue expected to decline more in 2026, is MaxCyte losing market share, and how can the business grow again? - Hannah Webb Hefley (Stephens Inc., Research Division)

2025Q2: Some customers have rationalized programs (a normal part of the business model), but new signings and clinical progress are offsetting this, maintaining 18 active clinical programs. - [Maher Masoud](CEO), [Douglas J. Swirsky](CFO)

Contradiction Point 5

Core Revenue Trajectory and Outlook

Guidance shifts from no expected demand improvement to being back-half weighted.

Matt Ito (Stephens) - Matt Ito (Stephens)

2025Q4: The core revenue guidance is back-half weighted and does not rely on an improvement in industry demand or customer capital spending. - [Maher Masoud](CEO)

With improved funding, what are customers' views on the macro environment and how should we anticipate demand in FY2026? - Dan Arias (Stifel)

2025Q1: The company is comfortable with a model showing modest sequential increases. This is not based on an expectation of market improvement. - [Doug Swirsky](CFO)